Holen Sie sich die Stockscreener-App
8.49
1.39%
-0.12
Handel nachbörslich:
8.47
-0.02
-0.24%
Schlusskurs vom Vortag:
$8.61
Offen:
$8.61
24-Stunden-Volumen:
837.94K
Relative Volume:
0.56
Marktkapitalisierung:
$749.92M
Einnahmen:
$67.48M
Nettoeinkommen (Verlust:
$-278.67M
KGV:
-2.672
EPS:
-3.1774
Netto-Cashflow:
$-70.70M
1W Leistung:
+9.83%
1M Leistung:
-5.25%
6M Leistung:
-13.37%
1J Leistung:
+44.14%
1-Tages-Spanne:
$8.46
$8.795
1-Wochen-Bereich:
$7.92
$8.935
52-Wochen-Spanne:
$5.41
$12.49
Kura Oncology Inc Stock (KURA) Company Profile
Firmenname
Kura Oncology Inc
Sektor
Branche
Telefon
(858) 500-8800
Adresse
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA
Compare KURA vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
8.49 | 760.52M | 67.48M | -278.67M | -70.70M | -3.1774 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-04 | Eingeleitet | Guggenheim | Neutral |
| 2025-02-06 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-14 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-22 | Eingeleitet | Mizuho | Buy |
| 2023-08-11 | Eingeleitet | BofA Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-05-17 | Eingeleitet | BTIG Research | Buy |
| 2023-01-31 | Eingeleitet | Stifel | Buy |
| 2022-07-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-02-15 | Eingeleitet | Jefferies | Buy |
| 2021-05-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-07 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-11-05 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Eingeleitet | Credit Suisse | Outperform |
| 2020-05-05 | Eingeleitet | Barclays | Overweight |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2018-11-09 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-08-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-10-13 | Fortgesetzt | Leerink Partners | Outperform |
| 2016-01-22 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-12-30 | Eingeleitet | Oppenheimer | Outperform |
| 2015-12-16 | Eingeleitet | Citigroup | Buy |
Alle ansehen
Kura Oncology Inc Aktie (KURA) Neueste Nachrichten
Breakout Move: Is Kura Oncology Inc vulnerable to short sellers2026 Market Sentiment & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule - National Today
Kura Oncology Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Kura Oncology Grants Inducement Stock Options to New Employees as Part of 2023 Inducement Option Plan - Quiver Quantitative
Cancer drugmaker Kura gives 6 new hires options on 153,750 shares - stocktitan.net
Kura Oncology (NASDAQ:KURA) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Kura Oncology: Commercialization In AML Presents Asymmetric Upside (NASDAQ:KURA) - Seeking Alpha
KURA Stock Price, Quote & Chart | KURA ONCOLOGY INC (NASDAQ:KURA) - ChartMill
Vanguard reports 0% ownership in Kura Oncology (NASDAQ: KURA) - Stock Titan
Kura Oncology Inc (HAM:KUR) Stock Price, Trades & News - GuruFocus
Kura Oncology (NASDAQ: KURA) CEO exercises options, increases share stake - Stock Titan
Mizuho Cuts Price Target on Kura Oncology to $25 From $30, Keeps Outperform Rating - marketscreener.com
Kura Oncology, Inc. (NASDAQ:KURA) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Kura Oncology, Inc. (NASDAQ:KURA) Receives Average Rating of "Moderate Buy" from Brokerages - marketbeat.com
Mizuho Cuts Kura Oncology (NASDAQ:KURA) Price Target to $25.00 - MarketBeat
Mizuho cuts Kura Oncology stock price target on delayed sales By Investing.com - Investing.com Canada
Mizuho Securities Maintains Kura Oncology(KURA.US) With Buy Rating, Cuts Target Price to $25 - Moomoo
Kura Oncology, Inc. (NASDAQ:KURA) Q4 2025 earnings call transcript - MSN
Kura Oncology Inc stock surges on positive mid-stage trial results for key cancer drug candidate - AD HOC NEWS
KURA SEC FilingsKura Oncology Inc 10-K, 10-Q, 8-K Forms - stocktitan.net
Jobs Data: Is Kura Oncology Inc a strong candidate for buy and holdMarket Sentiment Report & Trade Opportunity Analysis Reports - baoquankhu1.vn
Kura Oncology (KURA) director exercises 10,000 options for shares - Stock Titan
Kura Oncology Inc Stock (ISIN: US50126D1028) Faces Post-Earnings Pressure Amid Komzifti Launch Chall - AD HOC NEWS
Kura Oncology anticipates $7B AML opportunity as KOMZIFTI launches and combination strategies advance - MSN
UBS Maintains Buy on KURA (Kura Oncology) March 2026, PT $15 - Meyka
Prosight Management LP Sells 422,668 Shares of Kura Oncology, Inc. $KURA - MarketBeat
UBS lowers Kura Oncology stock price target to $15 on launch data - Investing.com Canada
Implied volatility surging for Kura Oncology stock options - MSN
Implied Volatility Soars for Kura Oncology Option Contracts - Bitget
Kura Oncology at Barclays Conference: Strategic Focus on Drug Combinations - Investing.com Canada
Implied Volatility Surging for Kura Oncology Stock Options - TradingView
(KURA) Risk Channels and Responsive Allocation - Stock Traders Daily
Kura Oncology Inc earnings missed by $0.66, revenue fell short of estimates - Investing.com Nigeria
Kura Oncology at Leerink Global Healthcare Conference: Strategic Expansion Insights - Investing.com Canada
KURA: Rapid market access and robust pipeline drive growth and leadership ambitions in precision oncology - TradingView
KURA: Multiple clinical readouts and strong commercial momentum position for leadership in targeted oncology - TradingView
FY2027 EPS Forecast for Kura Oncology Lowered by Analyst - MarketBeat
How The Kura Oncology (KURA) Story Is Shifting With Komzifti And New Street Targets - Yahoo Finance
Rhenman & Partners Asset Management AB Purchases 240,000 Shares of Kura Oncology, Inc. $KURA - MarketBeat
UBS Reaffirms Their Buy Rating on Kura Oncology (KURA) - The Globe and Mail
Kura Oncology rises after new early-stage trial data for leukemia therapy - MSN
Jim Cramer discusses Kura Oncology as a speculative bet - MSN
Kura Oncology 2025 Financials: Q4 Loss Widens, Misses Analyst EstimatesNews and Statistics - IndexBox
Kura Oncology Q4 2025 earnings preview - MSN
Kura Oncology, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:KURA) 2026-03-06 - Seeking Alpha
Kura Oncology, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Kura Oncology Reports $0.92 Q4 Loss Even as KOMZIFTI Debuts With $2.1M in Sales - AlphaStreet
Kura Oncology (NASDAQ:KURA) Given New $36.00 Price Target at Wedbush - MarketBeat
Kura Oncology, Inc. (NASDAQ:KURA) Q4 2025 Earnings Call Transcript - Insider Monkey
Kura Oncology reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Kura Oncology (KURA) Grants Stock Options to New Employees - GuruFocus
Finanzdaten der Kura Oncology Inc-Aktie (KURA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Kura Oncology Inc-Aktie (KURA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Malley Thomas | Director |
Mar 18 '26 |
Option Exercise |
3.12 |
10,000 |
31,200 |
10,000 |
| Powl Brian T. | Chief Commercial Officer |
Jan 27 '26 |
Sale |
8.46 |
6,414 |
54,266 |
183,275 |
| FORD KATHLEEN | Chief Operating Officer |
Jan 27 '26 |
Sale |
8.46 |
1,813 |
15,339 |
153,560 |
| Leoni Mollie | Chief Medical Officer |
Jan 27 '26 |
Sale |
8.46 |
8,180 |
69,209 |
267,274 |
| DOYLE THOMAS JAMES | SVP, Finance & Accounting |
Jan 27 '26 |
Sale |
8.46 |
7,142 |
60,426 |
145,167 |
| Burrows Francis | Chief Scientific Officer |
Jan 27 '26 |
Sale |
8.46 |
1,311 |
11,092 |
32,424 |
| Bair Teresa Brophy | Chief Legal Officer |
Jan 27 '26 |
Sale |
8.46 |
11,208 |
94,828 |
226,931 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):